Patent ID: 9078741
Filing Date: 2015-07-14
Classification: A61F,A61K,A61M,A61P,C12M,C12N

Abstract:
1. A cell suspension for direct application to a patient, said cell suspension produced according to a method comprising the steps of: (a) subjecting a skin tissue sample comprising dermis and epidermis bonded at a dermal-epidermal junction, to at least a physical and/or chemical dissociating means capable of dissociating cellular stratum in the skin tissue sample for sufficient time to weaken cohesive bonding between tissue stratum; (b) removing the skin tissue sample from the dissociating means used in step (a) and harvesting, in a reservoir containing a nutrient solution, cells from a dermal surface facing the dermal-epidermal junction and an epidermal surface facing the dermal-epidermal junction, wherein the nutrient solution is (i) free of xenogenic serum, (ii) capable of maintaining viability of the cells until applied to a patient and (iii) suitable for direct application to a recipient region on a patient, thereby to produce a mixed suspension of dermal and epidermal cells; and (c) filtering the mixed suspension of dermal and epidermal cells to remove large cellular conglomerates greater than 200 μm, to produce a cell suspension that is prepared peri-operatively and is directly applied to the patient; wherein the method does not comprise the steps of pelleting and resuspending the cells; wherein the filtered cells are substantially free of cellular stratum and are suspended in the nutrient solution such that the cell suspension is sprayable as airborne droplets.